https://www.selleckchem.com/pr....oducts/adenine-sulfa
CTCA was associated with a reduced rate of revascularisation [12.6% v 18.3%, fixed-effects model, OR 0.64 (0.55-0.75), p0.00001, I =0%]. However, CTCA was not associated with a significantly lower complication rate [0.5% v 1.72%, random effects model, OR 0.52 (0.06-4.38), p=0.55, I 52%]. CTCA is a safe strategy for investigating patients with stable angina with no associated increase in MACE but a reduction in revascularisation rates. CTCA is a safe strategy for investigating patients with stable angina with no associated in
Like
Comment
Share
